NCT04305041 · Interventional trial
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
Overall registry status Completed
Phase 1 · Phase 2
Conditions Melanoma
Delaware Valley sites
- University of Pennsylvania Abramson Cancer Center ( Site 1008) · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory